期刊文献+

老年冠心病CABG术后复发患者行PCI治疗的效果及预后

Effect and prognosis of PCI in elderly patients with coronary heart disease recurrence after CABG surgery
下载PDF
导出
摘要 目的:分析老年冠心病CABG术后复发行PCI治疗效果及对预后的影响。方法:回顾性分析2017年12月至2020年5月收治的92例患者资料,统计PCI手术效果、术后主要心血管事件和死亡情况。结果:治疗成功88.04%,MACE发生率22.22%,死亡率12.35%。发生组合并糖尿病、病变位置、支架植入桥血管、CABG时间、脂蛋白a、极低密度脂蛋白均高于未发生组,回归显示,糖尿病、支架植入桥血管、CABG时间长、Lpa、VLDL水平高是独立因素,CABG时间、Lpa、VLDL、支架植入桥血管是死亡独立因素。结论:PCI是治疗的有效手段,合并支架植入桥血管、CABG时间长、Lpa及VLDL水平高可增加PCI术后MACE和全因死亡风险。 Objective:To analyze the therapeutic effect and prognosis of recurrent PCI after CABG in elderly patients with coronary heart disease.Methods:the data of 92 patients who died after PCI from May 2017 to may 2020 were analyzed retrospectively.Results:the successful treatment was 88.04%,the incidence of mace was 22.22%,and the mortality was 12.35%.The incidence of combined diabetes mellitus,lesion location,stent graft,CABG time,lipoprotein A and very low density lipoprotein were all higher than those of the non occurrence group.Regression showed that diabetes,stent implantation,long CABG and high Lpa and VLDL levels were independent factors.CABG time,Lpa,VLDL and stent implantation were independent factors of death.Conclusion:PCI is an effective treatment.Combined with stent implantation,long CABG time and high levels of LPA and VLDL can increase the risk of mace and all-cause death after PCI.
作者 黄星 Huang Xing(Department of Cardiovascular Medicine,Meishan Hospital,West China Hospital,Sichuan University,Meishan 620000,China)
出处 《现代科学仪器》 2022年第2期86-89,133,共5页 Modern Scientific Instruments
关键词 冠状动脉旁路移植术 复发心绞痛 经皮冠状动脉介入术 老年 预后 Coronary artery bypass grafting Recurrent angina pectoris Percutaneous coronary intervention Elderly Prognosis
  • 相关文献

参考文献7

二级参考文献37

  • 1胡晓鹏,许建屏,胡盛寿,宋云虎,孙寒松,徐波.冠状动脉旁路移植术后桥血管造影特点分析[J].中国心血管病研究,2007,5(2):88-91. 被引量:9
  • 2Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery ( EACTS ), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J,2010 , 31:2501-2555.
  • 3Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation, 2011, 124 :e574-651.
  • 4Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coil Cardiol, 2011,58 :e123-210.
  • 5Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation ( EuroSCORE ). Eur J Cardiothorac Surg, 1999,16:9-13.
  • 6Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009,360:961- 972.
  • 7Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coil Cardiol,2010,55:1923-1932.
  • 8Online STS fish calculator [ S/OL]. [ 2012-01-01 ]. http:// riskcalc, sts. org/STSWebRiskCalc273/de, aspx.
  • 9Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes ( CURRENT-OASIS 7 ): a randomised factorial trial. Lancet,2010,376 : 1233-1243.
  • 10Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Cell Cardiol,2007,50 : 1742-1751.

共引文献454

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部